Spots Global Cancer Trial Database for lirilumab
Every month we try and update this database with for lirilumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor | NCT01750580 | CANCER, NOS | Lirilumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN | NCT03341936 | Squamous Cell C... | Nivolumab Lirilumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors | NCT01714739 | CANCER,NOS | Lirilumab Nivolumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) | NCT03347123 | Solid Tumors | Epacadostat Nivolumab Ipilimumab Lirilumab | 18 Years - | Incyte Corporation | |
| Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | NCT02599649 | Leukemia | Lirilumab Nivolumab Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | NCT02599649 | Leukemia | Lirilumab Nivolumab Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors | NCT01714739 | CANCER,NOS | Lirilumab Nivolumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | NCT01592370 | Non-Hodgkin's L... Hodgkin Lymphom... Multiple Myelom... | Nivolumab Ipilimumab Lirilumab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Bristol-Myers Squibb | |
| Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor | NCT01750580 | CANCER, NOS | Lirilumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors | NCT03203876 | Advanced Cancer | Lirilumab Nivolumab Ipilimumab | 20 Years - | Bristol-Myers Squibb | |
| Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT02399917 | Acute Biphenoty... Acute Myeloid L... Recurrent Acute... Refractory Acut... | Azacitidine Lirilumab | 18 Years - | M.D. Anderson Cancer Center | |
| An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | NCT01592370 | Non-Hodgkin's L... Hodgkin Lymphom... Multiple Myelom... | Nivolumab Ipilimumab Lirilumab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Bristol-Myers Squibb | |
| A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors | NCT01714739 | CANCER,NOS | Lirilumab Nivolumab Ipilimumab | 18 Years - | Bristol-Myers Squibb |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
